Category Archives: – NEJM

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

February 27, 2017- interviewed by Steven E. Greer, MD We interviewed Joaquim Bellmunt, MD, PhD, the Director of the Bladder Cancer Center at Dana-Farber,

Posted in - Biotech, - NEJM, - Pharma, Harvard, Oncology | Leave a comment

Aerobic or Resistance Exercise, or Both, in Dieting Obese Older Adults

June 14, 2017- Interviewed by Steven E. Greer, MD We interviewed Dennis Villareal, MD, the author of the NEJM paper “Aerobic or Resistance

Posted in - NEJM, Bariatric surgery, Baylor, Diabetes and endocrinology, Geriatrics, Internal Medicine | Leave a comment

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

January 12, 2017- Interviewed by Steven E. Greer, MD Jonathan Strosberg, MD of

Posted in - NEJM, Oncology | Leave a comment

The bionic pancreas data

July 2, 2014- Interviewed by Steven E. Greer, MD The New England Journal of Medicine recently published the early clinical data on the “bionic pancreas”

Posted in - Medical Devices, - NEJM, Boston University, Diabetes and endocrinology | Leave a comment

Ocrelizumab (Ocrevus) versus Placebo in Primary Progressive Multiple Sclerosis

January 31, 2017- Interviewed by Steven E. Greer, MD

Posted in - Biotech, - NEJM, - Pharma, Neurology, Univ Texas | 1 Comment

KIT inhibition by Gleevec (imatinib) for severe asthma

May 26, 2017- Interviewed by Steven E. Greer, MD Novartis’ Gleevec (imatinib) was approved in the U.S. in 2001 to treat leukemia. Now, researchers

Posted in - Biotech, - NEJM, - Pharma, National Jewish Health, Pulmonology | Leave a comment

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

May 23, 2017- interviewed by Steven E. Greer, MD We interviewed polumonologist Michael Wechsler, MD about his paper in the NEJM testing mepolizumab

Posted in - NEJM, National Jewish Health, Pulmonology, Rheumatology | Leave a comment

Are the new PCSK9 cholesterol lowering drugs worth the high cost?

December 16, 2015- Interviewed by Steven E. Greer, MD

Posted in - Biotech, - NEJM, - Opinion, - Pharma, - Policy, Cardiology, CMS, FDA | Leave a comment

Ibrance (palbociclib) to treat advanced breast cancer

November 28, 2016- Interviewed by Steven E. Greer, MD We interviewed Richard Finn, MD about his NEJM

Posted in - Biotech, - NEJM, - Pharma, Oncology, UCLA | Leave a comment

Is Vitamin-D deficiency overdiagnosed?

November 8, 2016- Interviewed by Steven E. Greer, MD We interviewed JoAnn E. Manson, MD, DrPH, Chief, Division of Preventive Medicine, Brigham

Posted in - NEJM, - Policy, CDC, Diabetes and endocrinology, FDA, Harvard, Primary care medicine | Leave a comment

The new CDC guidelines for prescribing opioid pain pills

June 1, 2016- Interviewed by Steven E. Greer, MD Pain pill prescriptions have quadrupled since the 1990’s as drug companies stepped up marketing and funded

Posted in - JAMA, - NEJM, - Pharma, CDC, Emergency medicine, General surgery, Oncology, Psychology Psychiatry, Rehab, Spine surgery, Sports medicine | Leave a comment

The ACA’s THC program: A pilot program to fund residency training outside of the traditional hospital setting

September 6, 2016- Interviewed by Steven E. Greer, MD

Posted in - NEJM, - Policy, CMS, George Washington Univ | Leave a comment

10-year follow-up on the CREST carotid stenting trial

March 4, 2016- Interviewed by Steven E. Greer, MD The 10-year follow-up data on the CREST carotid stenting vs. CEA trail were published

Posted in - Medical Devices, - NEJM, Cardiac surgery, Cardiology, Neurology, Neurosurgery, Vascular Surgery | Leave a comment

Single-pill combo regimens for HIV

July 28, 2014- Interviewed by Steven E. Greer, MD Rajesh Tim Gandhi, MD of the Massachusetts General Hospital discusses the NEJM review paper

Posted in - NEJM, Harvard, Infectious disease | Leave a comment

A second blow to Atul Gawande (and Obamacare)

December 15, 2015- by Steven E. Greer, MD Atul Gawande, MD, a surgeon working at one of the Harvard affiliated hospitals, wrote an influential essay in the

Posted in - NEJM, - Opinion, CMS, Congress, Harvard | Leave a comment

Preventing HIV infection

July 28, 2014- Interviewed by Steven E. Greer, MD Rajesh Tim Gandhi, MD of the Massachusetts General Hospital discusses the NEJM review paper he co-wrote

Posted in - Biotech, - NEJM, - Pharma, General surgery, Harvard, Infectious disease, Primary care medicine | Leave a comment

Eluxadoline (Viberzi) to treat Irritable Bowel Syndrome

January 20, 2016- Produced, Interviewed by Steven E. Greer, MD We interviewed Anthony Lembo, MD of The Beth Israel Deaconess Hospital to discuss his

Posted in - NEJM, - Pharma, Gastroenterology and liver, Harvard | Leave a comment

The telomerase inhibitor Imetelstat developed by Geron

September 9, 2015-

Posted in - Biotech, - NEJM, Oncology | Leave a comment

How did a small academic lab succeed where big medical device companies failed?

July 5, 2014- Interviewed by Steven E. Greer, MD The New England Journal of Medicine recently published the early clinical data on the “bionic pancreas”

Posted in - Medical Devices, - NEJM, Boston University, Diabetes and endocrinology | Leave a comment

CT-scan screening for heart disease fails to show benefit

March 23, 2015- Interviewed by Steven E. Greer, MD We interviewed the Principal Investigator of the PROMISE trial, Pamela Douglas, MD from Duke.

Posted in - NEJM, - Policy, Cardiology, CMS, Duke, Radiology | Leave a comment